泰的T1 -快速基因组第一和second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01796-2020 VL - 57 IS - 1 SP - 2001796 AU - Feuerriegel, Silke AU - Kohl, Thomas A. AU - Utpatel, Christian AU - Andres, Sönke AU - Maurer, Florian P. AU - Heyckendorf, Jan AU - Jouet, Agathe AU - Badalato, Nelly AU - Foray, Lynda AU - Fouad Kamara, Rashidatu AU - Conteh, Osman S. AU - Supply, Philip AU - Niemann, Stefan Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/57/1/2001796.abstract N2 - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis complex (Mtbc) isolates challenges tuberculosis (TB) control worldwide [1] and requires the rapid determination of extensive resistance profiles [2], enabling prompt initiation of effective treatment regimens. Phenotypic drug susceptibility testing (pDST) takes up to 6 weeks [3], and is unreliable and/or not standardised for several drugs, according to World Health Organization (WHO) guidelines [4]. Molecular DST (mDST) assays, like Xpert MTB/RIF (Cepheid) or MTBDRplus/sl line probe assays (LPAs; Hain Lifesciences) can be performed directly from clinical specimens, but only target a limited number of resistance variants [5].Targeted next generation sequencing using the Deeplex-MycTB assay can rapidly generate comprehensive drug resistance profiles from Mycobacterium tuberculosis complex cultures and directly from tuberculosis patient samples to guide personalised treatment https://bit.ly/3dP1eIpWe thank Tanja Niemann, Vanessa Mohr and Fenja Boysen, Molecular and Experimental Mycobacteriology, Research Centre Borstel, Borstel, Germany, for excellent technical assistance. ER -